Evidence map›Paper›PMID 41925800›Full record

ArticleMolecular and cellular biochemistry2026

S-equol promotes ferroptosis in triple negative breast cancer by coordinating NCOA4-mediated ferritinophagy and PPARγ-mediated lipid metabolism.

Fubiao Ni, Ziyang Huang, Yuekai Cui, Pengwei Huang, Zhiyuan Xue, Guiqian Huang, Yaxin Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fubiao Ni *Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Ziyang Huang *Department of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Yuekai CuiDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Pengwei HuangThe Second School of Medicine, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Zhiyuan XueDepartment of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Guiqian HuangSchool of Mental Health, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. huangguiqian@wmu.edu.cn.
Yaxin ZhaoDepartment of Breast Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. zyx@wmu.edu.cn.

Funding

Program of Wenzhou Association for Integrated Chinese and Western Medicine 2021002Scientific Research Project of Zhejiang Provincial Department of Education Y202250025
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is a diverse and highly aggressive cancer characterized by a strong tendency to metastasize, poor prognosis, and a lack of effective therapeutic targets. S-equol, an active metabolinte produced by gut microbiota through the conversion of daidzein, has been proven to possess anticancer activity. This study aims to investigate the anticancer effects of S-equol on TNBC and to elucidate key targets and potential mechanisms. In vitro experiments utilized the TNBC cell lines, while in vivo experiments employed a nude mouse xenograft tumor model. By means of using CCK-8, colony formation, scratch, and transwell invasion assays, the biological function of S-equol was evaluated. In addition, bioinformatics methods were employed to explore the potential signaling pathways and target genes of S-equol. The in vitro results substantiated that S-equol significantly suppressed both the proliferation and metastatic capacity of TNBC cells. Moreover, the prediction results indicated that S-equol may exert its anti-TNBC effects through ferroptosis via the PI3K/AKT signaling pathway, with PPARγ identified as the key gene. In vitro and in vivo results collectively verified that S-equol triggers ferroptosis by influencing lipid peroxidation and Fe²

Indexed as

EquolFerroptosisLipid MetabolismNuclear Receptor CoactivatorsPPAR gammaTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMice, NudeSignal TransductionXenograft Model Antitumor AssaysEquolNCOA4 protein, humanNuclear Receptor CoactivatorsPPAR gammaPPARG protein, humanFerroptosisNCOA4PPARγS-equolTriple-negative breast cancer

Identifiers

PMID41925800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.